Business
Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, Sept. 20 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today\nannounced the market launch of its EAA(TM) Endotoxin Activity Assay, a rapid\ndiagnostic product for sepsis, in Germany through A. Menarini Diagnostics\nDeutschland ("Menarini"), a division of the Italian Menarini Group. Sepsis is\nthe third most common cause of death in Germany with 60,000 victims each year.\nThe treatment of severe sepsis consumes about one third of intensive care\nunits' budgets in Germany ((euro) 1.7 billion per year), emphasizing the need\nfor early detection of sepsis.\n\n\n"The German launch represents a significant milestone in the\ncommercialization of our EAA(TM) rapid sepsis diagnostic and follows several\nmonths of extensive research by our partner Menarini," stated Dr. Paul Walker,\nPresident & CEO of Spectral. "Germany is the largest healthcare market in the\nEU and we are quite confident that with Menarini's broad and experienced sales\npresence we are well positioned to make a successful entry into this market\nand set the stage for expansion into the rest of Europe in 2008."\n\n\nMenarini Diagnostics was founded in 1976 as a division of A. Menarini\nIndustrie Farmaceutiche Riunite of Florence, Italy, a multinational healthcare\ncompany with annual revenues of more than 2.2 billion Euros, with eleven\nwholly owned subsidiaries in Austria, Belgium, France, Germany, Greece, Italy,\nthe Netherlands, Portugal, Spain, United Kingdom and Sweden. Menarini\nDiagnostics had 2005 consolidated revenues of approximately 256 million Euros\nand currently employs approximately 700 people, 75% of whom are dedicated to\nmarketing, sales, after-sales service and customer care activities.\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral technologies provide accurate and timely\ninformation to clinicians enabling the early initiation of appropriate and\ntargeted therapy. Current products include Spectral's FDA approved rapid\ndiagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid\ndiagnostic for sepsis (EAA(TM)), as well as a range of other biological\nreagents.\n\n\nInformation in this news release that is not current or historical\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. I...